Treatment With Solifenacin Increases Warning Time and Improves Symptoms of Overactive Bladder: Results From VENUS, a Randomized, Double-Blind, Placebo-Controlled Trial

Urology

Volumn 73, Issue 1, 2009, Pages 14-18

  Karram, Mickey M ^a   Toglia, Marc R ^b   Serels, Scott R ^c   Andoh, Masakazu ^d   Fakhoury, Allam ^d   Forero Schwanhaeuser, Sergio ^e  

^a Advanced Urogynecology and Pelvic Surgery   (United States)

^b Urogynecology Associates of Philadelphia   (United States)

^c Bladder Control Center of Norwalk   (United States)

^d ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

^e GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; SOLIFENACIN;

ADULT; AGED; ARTICLE; BLURRED VISION; CONSTIPATION; CONTROLLED STUDY; DIZZINESS; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERACTIVE BLADDER; PRIORITY JOURNAL; TIME; TREATMENT DURATION; TREATMENT RESPONSE; URINARY FREQUENCY; XEROSTOMIA;

AGED; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; QUINUCLIDINES; TETRAHYDROISOQUINOLINES; TIME FACTORS; URINARY BLADDER, OVERACTIVE; URINATION;

EID: 57849162746     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2008.08.485     Document Type: Article

References (16)

1. Abrams P., Cardozo L., Fall M., et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-Committee of the International Continence Society. Neurourol Urodyn. 21 (2002) 167-178
2. Abrams P., Blaivas J.G., Stanton S.L., et al. The standardisation of terminology of lower urinary tract function. The International Continence Society Committee on Standardisation of Terminology. Scand J Urol Nephrol Suppl. 114 (1988) 5-19
3. Chapple C.R., Artibani W., Cardozo L.D., et al. The role of urinary urgency and its measurement in the overactive bladder symptom syndrome: current concepts and future prospects. BJU Int. 95 (2005) 335-340
4. Abrams P. Urgency: the key to defining the overactive bladder. BJU Int. 96 Suppl 1 (2005) 1-3
5. Brunton S., and Kuritzky L. Recent developments in the management of overactive bladder: focus on the efficacy and tolerability of once daily solifenacin succinate 5 mg. Curr Med Res Opin. 21 (2005) 71-80
6. Hegde S.S. Muscarinic receptors in the bladder: from basic research to therapeutics. Br J Pharmacol. 147 Suppl 2 (2006) S80-S87
7. Staskin D.R., and MacDiarmid S.A. Pharmacologic management of overactive bladder: practical options for the primary care physician. Am J Med. 119 (2006) 24-28
8. Cardozo L., Lisec M., Millard R., et al. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol. 172 (2004) 1919-1924
9. Chapple C.R., Cardozo L., Steers W.D., et al. Solifenacin significantly improves all symptoms of overactive bladder syndrome. Int J Clin Pract. 60 (2006) 959-966
10. Chapple C.R., Martinez-Garcia R., Selvaggi L., et al. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol. 48 (2005) 464-470
11. Cardozo L., and Dixon A. Increased warning time with darifenacin: a new concept in the management of urinary urgency. J Urol. 173 (2005) 1214-1218
12. Zinner N., Susset J., Gittelman M., et al. Efficacy, tolerability and safety of darifenacin, an M(3) selective receptor antagonist: an investigation of warning time in patients with OAB. Int J Clin Pract. 60 (2006) 119-126
13. Wang A.C., Chih S.Y., and Chen M.C. Comparison of electric stimulation and oxybutynin chloride in management of overactive bladder with special reference to urinary urgency: a randomized placebo-controlled trial. Urology 68 (2006) 999-1004
14. Khullar V., Hill S., Solanki J., et al. Tolterodine increases the urgency-free time interval: a sensory and motor effect?. (Abstract 172 presented at the Joint Meeting of the International Continence Society and the International UroGynecological Association, 34th Annual Meeting, Paris, France, 25-27 August 2004). Neurourol Urodyn. 23 (2004) 387-616
15. Choi H.K., Xin Z.C., Choi Y.D., et al. Safety and efficacy study with various doses of SS-cream in patients with premature ejaculation in a double-blind, randomized, placebo controlled clinical study. Int J Impot Res. 11 (1999) 261-264
16. Chapple C.R., Rechberger T., Al-Shukri S., et al. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int. 93 (2004) 303-310